Triclabendazole in the treatment of human fascioliasis: a community-based study.
The efficacy of triclabendazole in the treatment of chronic Fasciola infection was assessed. A total of 134 asymptomatic cases of established Fasciola infection were treated: 68 individuals received a single dose of 10 mg/kg and 66 individuals received 2 doses of 10 mg/kg on 2 consecutive days. Cure was assessed 5 weeks after treatment and 79.4% of the first group and 93.9% of the second group were cured. The drug was well tolerated; no serious side-effects were noted. One patient developed biochemical cholestasis the third day after treatment, but her enzyme profiles returned to normal after 2 months. We conclude triclabendazole is a safe and potent fasciolicidic drug.
el-Morshedy
H
H
Department of Tropical Health, University of Alexandria, Egypt.
Farghaly
A
A
Sharaf
S
S
Abou-Basha
L
L
Barakat
R
R
D000293:Adolescent; D000328:Adult; D000871:Anthelmintics / Q000008:administration & dosage* / Q000009:adverse effects; D001562:Benzimidazoles / Q000008:administration & dosage* / Q000009:adverse effects; D002648:Child; D002675:Child, Preschool; D002779:Cholestasis / Q000139:chemically induced / Q000201:enzymology; D002908:Chronic Disease; D004334:Drug Administration Schedule; D004534:Egypt / Q000453:epidemiology; D019353:Endemic Diseases / Q000517:prevention & control; D005211:Fascioliasis / Q000188:drug therapy* / Q000453:epidemiology / Q000469:parasitology; D005260:Female; D006801:Humans; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome; D000077682:Triclabendazole
D000871:Anthelmintics; D001562:Benzimidazoles; D000077682:Triclabendazole